NCT07104032View on ClinicalTrials.gov

Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Relapsed/Refractory Primary Central Nervous System Lymphoma
Interventions
DRUG

Tirabrutinib

Administered orally.

DRUG

Rituximab

Administered intravenously (IV).

DRUG

Temozolomide

Administered orally.

Sponsors
All Listed Sponsors
collaborator

Deciphera Pharmaceuticals, LLC

INDUSTRY

lead

Ono Pharmaceutical Co. Ltd

INDUSTRY